Biotechnology

Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin(R) Therapeutic Candidate MP0420

November 23, 2020 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / November 23, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that a first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420 (ensovibep), a DARPin® therapeutic candidate for the potential treatment and prevention of COVID-19....

Read more

American Screening LLC Facilitates Efficient Decision-Making with Vast Selection of Rapid Drug Tests

November 19, 2020 11:35 PM

SHREVEPORT, LA / ACCESSWIRE / November 19, 2020 / Despite the social progress and economic prosperity achieved in the past few decades, certain issues remain a common challenge for nations worldwide. One of them is illicit drug use, which has been straining healthcare budgets, affecting workplace productivity, and endangering public safety. However, medical and technological advances have enabled government agencies, healthcare professionals,...

Read more

ITOCO Releases Current List of "Time Of Presentation" (TOP) Verification Solutions That Address Virus Testing on Its Blog

November 19, 2020 7:44 AM

TORONTO, ON / ACCESSWIRE / November 19, 2020 / ITOCO INC. (OTC PINK:ITMC) has released a list of companies and organizations addressing Virus testing through time-of-presentation (TOP) solutions. TOP solutions provide updated status of vaccination and/or testing at point of contact. Time of Presentation verification solutions refer to systems which uses verification to prove that a person presenting themselves to an event, physical...

Read more

Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M

November 19, 2020 6:30 AM

Asset Sale in Preparation for US National Securities Exchange Listing KELOWNA, BC / ACCESSWIRE / November 19, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, has entered a definitive asset purchase agreement (the "Agreement"), through its wholly owned subsidiary Lexaria Canpharm ULC ("CanPharm"), to sell certain non-core, non-pharmaceutical THC-related...

Read more

NovAccess Global Secures Worldwide Rights to Approved Patent

November 18, 2020 9:00 AM

Provides advancement for its immunotherapy technology against brain tumors into human clinical trials CLEVELAND, OH / ACCESSWIRE / November 18, 2020 / NovAccess Global Inc. (OTC PINK:XSNX) (the "Company" or "NovAccess"), a cancer therapeutics company with operations in biotechnology is thrilled to announce that it has an unlimited use license to an approved US Patent # 9764014, which was obtained in September 2020 when NovAccess acquired...

Read more

Bio Lab Naturals, Inc.'s Subsidiary Signs Exclusive Distribution Agreement

November 18, 2020 8:00 AM

GREENWOOD VILLAGE, CO / ACCESSWIRE / November 18, 2020 / Bio Lab Naturals, Inc. ("BLAB" or the "Company") (OTCQB:BLAB) announces today that its subsidiary, Prime Time Live, Inc. ("PTL") signed an Exclusive Distribution Agreement on November 13, 2020 with Insane Impact, LLC ("Insane Impact"), an Iowa limited liability company, to act as Insane Impact's exclusive distributor of Insane Impact Products. Insane Impact shall provide leads of LED...

Read more

Lumira Ventures Appoints Special Advisors and Venture Partner

November 18, 2020 5:00 AM

Veteran Pharmaceutical Industry Executives Will Advise Portfolio Companies and Investment Team TORONTO, ON / ACCESSWIRE / November 18, 2020 / Lumira Ventures, a leading North American healthcare venture capital firm, today announced the appointment of Theodore Witek, Jr., DrPH, MBA and Daniel Billen, PhD to the role of Special Advisor, and Sena Biswas, PhD, MBA as Venture Partner. "We are excited to welcome Ted, Daniel and Sena to the...

Read more

Mymetics to Advance Preclinical Studies for Virosome-based COVID-19 Vaccine through Innosuisse Grant

November 18, 2020 3:00 AM

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. Mymetics, through its collaborator, the Department of Pneumology at the Inselspital, Bern University Hospital, in Switzerland, have received a grant from the Swiss Innovation Agency (Innosuisse) to investigate Mymetics' intranasal Covid-19 vaccine candidates in preclinical studies. This new study will complement...

Read more

American Screening LLC Offers Comprehensive Choice of Urine and Saliva Drug Tests

November 17, 2020 9:10 PM

SHREVEPORT, LA / ACCESSWIRE / November 17, 2020 / For close to 17 years, American Screening LLC has been supporting efforts to combat substance abuse and addiction by providing a vast array of drug testing products and striving to offer the best possible prices without compromising on quality. This has helped the Shreveport, Louisiana-based company become an ISO13485 contract manufacturer and one of the leading distributors of diagnostic...

Read more

New Biotech Product From Merion Helps To Increase Metabolism and Support Anti-Aging

November 17, 2020 1:00 PM

NMN+++ product contains powerful NMN nucleotide LOS ANGELES, CA / ACCESSWIRE / November 17, 2020 / A new biotech product from Merion Inc. (OTCQB:EWLU) can help to increase metabolism, repair DNA and support anti-aging. The NMN+++ product contains the key ingredient nicotinamide mononucleotide (NMN). Scientists from the University of New South Wales and Harvard University have found that NMN can transform the bodily age indicators of...

Read more

BioLargo Revenue Continues Breaking Records as Water Technologies Ready for Commercialization

November 16, 2020 6:30 PM

Technology Portfolio Expanding WESTMINSTER, CA / ACCESSWIRE / November 16, 2020 / BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, filed with the SEC its Quarterly Report on Form 10-Q for the period ended September 30, 2020 (www.biolargo.com/sec-filings). BioLargo's Third Quarter Accomplishments Record revenue - generated record revenues in the third quarter,...

Read more

Citizen Stash Launches New Line of Cannabis Edibles

November 16, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / November 16, 2020 / Experion Holdings Ltd. (the "Corporation" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to announce it has now produced and shipped its first cannabis edible under its nationally recognized Citizen Stash brand. Designed for the legal adult recreational market Experion's initial shipment of its edible gummies product line will be directed first to Saskatchewan, with order...

Read more

Tetra Bio-Pharma Provides Update on Recent Milestones

November 16, 2020 6:30 AM

Plenitude Trial initiated Tetra completes clinical study assessing the metabolism profile of cannabinoids in humans Achieved development of ARDS-003 sterile injectable nano-emulsion for human use OTTAWA, ON / ACCESSWIRE / November 16, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today provided an update on its ARDS-003, CAUMZ™, PPP-003...

Read more

PDS Biotech to Present at the Virtual Fall Investor Summit on November 16th-18th

November 13, 2020 3:00 PM

NEW YORK, NY / ACCESSWIRE / November 13, 2020 / PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, Chief Executive Officer, will be presenting at this year's virtual Fall Investor Summit taking place November 16th-18th, 2020. The...

Read more

Applied UV Announces Closing of $7,360,000 Public Offering Including Full Exercise of Overallotment Option

November 13, 2020 10:35 AM

MOUNT VERNON, NY / ACCESSWIRE / November 13, 2020 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of narrow-range ultra violet light ("UVC") to destroy pathogens safely, thoroughly, and automatically, today announced today's closing of its public offering of 1,401,905 shares of its common stock at a price of $5.25 per share including the underwriter's exercise in...

Read more

Enzolytics Inc. Shares Current BioClonetics Immunotherapeutics, Inc. Update

November 13, 2020 9:00 AM

PLANO, TX / ACCESSWIRE / November 13, 2020 / Enzolytics Inc. (OTC PINK:ENZC) or the "Company" today shared the following update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), resulting from the application of proceeds from the initial funding received on October 26, 2020. The full text of the update is presented below. November 13, 2020 Dear Investors and Supporters, We are making...

Read more

Xenetic Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 13, 2020 8:00 AM

- Continued Advancement of XCART™ Platform Towards an IND Filing and Phase 1 Study - Leveraging Partnerships With Leading Global Academic Institutions, Including Scripps Research FRAMINGHAM, MA / ACCESSWIRE / November 13, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and...

Read more

Dyadic Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress

November 12, 2020 4:30 PM

Six new and expanded animal and human health collaborations since Q2 2020 Expanded presence in the Asia Pacific Region Important progress and expanded animal efficacy data in COVID-19 vaccine and antibody programs ZAPI to conduct additional animal studies for Schmallenberg Virus (SBV) and initiate animal studies for Rift Valley Fever Virus (RVFV) Continued strong financial position at end of third quarter JUPITER, FL / ACCESSWIRE / November 12,...

Read more

Integrated BioPharma Reports Results for its Quarter Ended September 30, 2020

November 12, 2020 4:30 PM

HILLSIDE, NJ / ACCESSWIRE / November 12, 2020 / Integrated BioPharma, Inc. (OTCQB:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2020. Revenue for the quarter ended September 30, 2020 was $15.2 million compared to $11.4 million for the quarter ended September 30, 2019, an increase of $3.8 million or 33.0%. The Company had operating income for the quarter ended September 30, 2020 of $1.5...

Read more

MustGrow Biologics Corp to Present at the virtual Fall Investor Summit on November 16th-18th

November 12, 2020 9:50 AM

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / MustGrow Biologics Corp (OTCQB:MGROF), an agriculture bio-tech company focused on providing natural, science-based biological solutions to replace synthetic chemicals, will be presenting at this year's virtual Fall Investor Summit on November 16th-18th. The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors. About MustGrow...

Read more